Drug Profile
Research programme: cyclin-dependent kinase inhibitors - GPC Biotech
Alternative Names: GPC 285978; GPC 286199; RGB-286199; RGB-344064Latest Information Update: 13 Jul 2010
Price :
$50
*
At a glance
- Originator GPC Biotech AG
- Developer Agennix AG
- Class Pyrazoles; Small molecules
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 Aug 2007 GPC Biotech slows down certain ongoing activities and no further commitments to be made to its cell-cyle inhibitor programme; development is suspended until further resources are available
- 02 May 2006 Preclinical trials in Cancer in USA (unspecified route)
- 21 Jun 2005 This programme is still in active development